Physician profile
Magdalena Ramirez
NPI 1255089777
$1,180.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $612 · 2023: $518 · 2024: $51.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $347.38 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $255.23 | 2022-2023 | |
| Intuity Medical INC | $148.90 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Kowa Pharmaceuticals America, INC. | $85.89 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.80 | 2023 | |
| Inspire Medical Systems, INC. | $45.14 | 2023-2024 | Inspire |
| Abbvie INC. | $38.48 | 2022 | |
| Corcept Therapeutics | $28.49 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $28.05 | 2023 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $25.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.93 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.37 | 2023 | Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $19.23 | 2022 | |
| Amarin Pharma, INC. | $18.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdalena Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.